Company Filing History:
Years Active: 2013
Title: The Innovations of Inventor Isabelle Roland in Pancreatic Beta Cell Research
Introduction
Isabelle Roland, based in Namur, Belgium, is an accomplished inventor with a significant contribution to the field of biomedical research. Her patent focuses on a unique biomarker that has the potential to enhance the understanding and targeting of pancreatic beta cells, which play a crucial role in glucose regulation and diabetes management.
Latest Patents
Isabelle Roland holds a patent titled "Plasma membrane biomarkers preferentially expressed in pancreatic beta cells useful in imaging or targeting beta cells." This invention targets the identification of a biomarker located specifically in the plasma membrane of pancreatic beta cells. The biomarker was selected through a Systems Biology approach utilizing Massively Parallel Signal Sequencing datasets, which were obtained from human islets, along with Affymetrix microarray datasets on purified rat primary beta and non-beta cells, in addition to insulinoma cells.
The biomarker has several notable features that make it a unique candidate for imaging and targeting strategies aimed at studying pancreatic beta cell mass in various health conditions, including Type 1 Diabetes (T1D), Type 2 Diabetes (T2D), pancreatic cancers, obesity, islet transplantation, and beta cell regeneration.
The five specific features of the selected biomarker include:
1. Preferential expression in pancreatic islets compared to surrounding tissues.
2. Higher expression levels in pancreatic beta cells than in alpha cells or other non-beta cells within the islet.
3. Comparable or higher expression levels in pancreatic beta cells relative to glucokinase, an enzyme notably expressed in these cells.
4. Membrane localization, allowing for targeting with antibodies, peptides, or small molecules, which facilitates imaging, targeting, and immunohistochemistry.
5. Non-induction of expression during the inflammation process of beta cell mass, and protein specificity that is not enriched in T-cells, dendritic cells, or other inflammation-participating cells.
Career Highlights
Isabelle is currently affiliated with Université Libre De Bruxelles, where she continues her research endeavors and contributes to advancements in the medical field. Her singular patent marks a significant milestone in her career, exemplifying her commitment to innovation and tackling complex challenges in health science.
Collaborations
Throughout her career, Isabelle has worked alongside esteemed colleagues, including Decio L. Eizirik and Daisy Flamez. Their collaborative efforts demonstrate a concerted approach in the search for effective strategies to study and address issues related to pancreatic beta cell functionality and health.
Conclusion
Isabelle Roland's work is a testament to the impactful role of inventors in advancing medical science. Her patent on pancreatic beta cell biomarkers not only enhances the understanding of beta cell dynamics but also paves the way for innovative therapeutic strategies in diabetes and related conditions. Through her contributions, she exemplifies the critical intersection of scientific research and practical innovation, reflecting the vital work of inventors in today's health landscape.